DES For Vulnerable Plaque: Consensus Elusive With Current Imaging Tools
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stents should not be viewed as the definitive treatment for vulnerable plaque, according to David Holmes, MD, Mayo Clinic
You may also be interested in...
BMS/Thermocore pact for vulnerable plaque
Bristol-Myers Squibb gains worldwide development, manufacturing and commercialization rights to Thermocore intracoronary thermographic catheter system technology designed to detect vulnerable plaque by mapping temperature variations inside coronary arteries. Rupture of vulnerable plaque is a prime cause of heart attack. Initial clinical trials will focus on assessing the prognostic value of the device, according to BMS. During a vulnerable plaque summit at the May CRT 2004 conference in Washington, D.C., participants generally agreed that no accurate imaging tools currently exist to detect vulnerable plaque 1"The Gray Sheet" May 10, 2004, p. 4)...
BMS/Thermocore pact for vulnerable plaque
Bristol-Myers Squibb gains worldwide development, manufacturing and commercialization rights to Thermocore intracoronary thermographic catheter system technology designed to detect vulnerable plaque by mapping temperature variations inside coronary arteries. Rupture of vulnerable plaque is a prime cause of heart attack. Initial clinical trials will focus on assessing the prognostic value of the device, according to BMS. During a vulnerable plaque summit at the May CRT 2004 conference in Washington, D.C., participants generally agreed that no accurate imaging tools currently exist to detect vulnerable plaque 1"The Gray Sheet" May 10, 2004, p. 4)...
Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Guidant is backing its previously stated pledge to develop a market for the diagnosis and treatment of vulnerable plaque, investing in Miravant Medical Technologies' PhotoPoint photodynamic therapy